Clinical trial
A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of…
NCT00391222 · Janssen Pharmaceutica N.V., Belgium, Industry · Completed
Key facts
| NCT number | NCT00391222 |
|---|---|
| Title | A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I Disorder |
| Official title | A Randomized, Double Blind, Placebo and Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Risperidone Long-acting Injectable (LAI) for the Prevention of Mood Episodes in the Treatment of Subjects With Bipolar I Disorder |
| Lead sponsor | Janssen Pharmaceutica N.V., Belgium, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Bipolar Disorder |
| Intervention type | Drug |
| Interventions | Olanzapine, Placebo, Risperidone Long Acting Injectable (LAI) |
| Enrollment | 585 |
| Start date | Nov 1, 2006 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Oct 23, 2006 |
| Last update posted | May 9, 2014 |
| Countries | China, Colombia, Germany, Greece, India, Indonesia, Jordan, Lebanon, Malaysia, Mexico, Peru, Philippines and 3 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: